{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:31:25Z","timestamp":1787391085766,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,21]]},"DOI":"10.7759\/cureus.111235","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:40:24Z","timestamp":1782052824000},"source":"Crossref","is-referenced-by-count":1,"title":["Cytomegalovirus (CMV) Co-infection in Treatment-Refractory Immune Checkpoint Inhibitor-Associated Colitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Michael","family":"Stanczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer","volume":"9","author":"Iranzo P","year":"2022","unstructured":"Iranzo P, Callejo A, Assaf JD, et al.. Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer. Front Med (Lausanne). 2022, 9:875974. 10.3389\/fmed.2022.875974","journal-title":"Front Med (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin Q","year":"2023","unstructured":"Yin Q, Wu L, Han L, et al.. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023, 14:1167975. 10.3389\/fimmu.2023.1167975","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang DY","year":"2017","unstructured":"Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017, 6:e1344805. 10.1080\/2162402X.2017.1344805","journal-title":"Oncoimmunology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan M","year":"2021","unstructured":"Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021, 160:1384-1393. 10.1053\/j.gastro.2020.08.063","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-1768. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-9-199311010-00010","article-title":"Gastrointestinal cytomegalovirus disease","volume":"119","author":"Goodgame RW","year":"1993","unstructured":"Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993, 119:924-935. 10.7326\/0003-4819-119-9-199311010-00010","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00869.x","article-title":"Cytomegalovirus colitis complicating inflammatory bowel disease","volume":"101","author":"Kandiel A","year":"2006","unstructured":"Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006, 101:2857-2865. 10.1111\/j.1572-0241.2006.00869.x","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey L","year":"2016","unstructured":"Marthey L, Mateus C, Mussini C, et al.. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016, 10:395-401. 10.1093\/ecco-jcc\/jjv227","journal-title":"J Crohns Colitis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10140-020-01750-z","article-title":"Clinical, imaging, endoscopic findings, and management of patients with CMV colitis: a single-institute experience","volume":"27","author":"Shieh AC","year":"2020","unstructured":"Shieh AC, Guler E, Tirumani SH, Dumot J, Ramaiya NH. Clinical, imaging, endoscopic findings, and management of patients with CMV colitis: a single-institute experience. Emerg Radiol. 2020, 27:277-284. 10.1007\/s10140-020-01750-z","journal-title":"Emerg Radiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034463","article-title":"Tissue quantitative RT-PCR test for diagnostic significance of cytomegalovirus infection in patients with inflammatory bowel disease and treatment response: cytomegalovirus infection in patients with inflammatory bowel disease","volume":"102","author":"Ozdemir B","year":"2023","unstructured":"Ozdemir B, Atay A, Kayhan MA, Ozin YO, Gokce DT, Altunsoy A, Guner R. Tissue quantitative RT-PCR test for diagnostic significance of cytomegalovirus infection in patients with inflammatory bowel disease and treatment response: cytomegalovirus infection in patients with inflammatory bowel disease. Medicine (Baltimore). 2023, 102:e34463. 10.1097\/MD.0000000000034463","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502995-cytomegalovirus-cmv-co-infection-in-treatment-refractory-immune-checkpoint-inhibitor-associated-colitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:40:25Z","timestamp":1782052825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502995-cytomegalovirus-cmv-co-infection-in-treatment-refractory-immune-checkpoint-inhibitor-associated-colitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.111235","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,21]]}}}